Andrew P

[Andrew P @pushandr_]

@Williams998661 Unfortunately they got it wrong scapegoating Dyatlov, in reality Legasov is covering up and shifting blame from soviet state and his research org to the station operators… can’t recommend this channel enough https://t.co/c7yQj2lqLr

[Houman David Hemmati, MD, PhD @houmanhemmati]

😳 AMAZING scientific advance published today by @ScienceTM!

A previously untreatable mutation in a patient with cystic fibrosis was corrected in patient-derived organoids in vitro with GENE EDITING!

Huge news because it proves that challenging genetic diseases can potentially be fixed by correcting the mutation itself without inserting a whole new gene (gene therapy), something that carries risks & may be unfeasible (gene too long to insert).

We are nearing a very different era when it comes to genetic diseases!

[David R. Liu @davidrliu]

Today in @natBME we report an in vivo base editing strategy that corrects a common disease-causing mutation and rescues pathology in a mouse model of Zellweger spectrum disorder (ZSD) and restore peroxisomal function in patient derived cells. This work highlights the promise of precision genome editing for treating peroxisomal biogenesis disorders.
1/13

[Andrew P @pushandr_]

@cemaxecuter Really curious to see if it works seamlessly with uhd and open source RAN like srs/OAI please keep us posted ;)

[Andrew P @pushandr_]

@medstudentinvst @aditharun_ Hi and what about arbitration with beam?

[Andrew P @pushandr_]

@yaireinhorn Looks like unproven but superior modality to crispr derived editors, I like their directed evolution approach similar to what Liu lab was doing to improve their platform

[Andrew P @pushandr_]

@yaireinhorn Hey do you think Prime will get the PERT tech eventually and have some pipeline extension for this promising approach?

[Andrew P @pushandr_]

@techinvestoor @crisprspace Do you think Prime Medicine will have the PERT tech or would it be spin off again with a new company?

[Andrew P @pushandr_]

@novapharma So now we should wait till Monday or it could happen over weekend?

[David R. Liu @davidrliu]

Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature stop codons across different diseases.
(1/15)
https://t.co/zs0qu5bhXx

[Andrew P @pushandr_]

@CrisprCIO that article have nothing to do with prime

[Andrew P @pushandr_]

@matti7777 @JessieChimni https://t.co/Fj9feowLIi

[Andrew P @pushandr_]

@matti7777 @JessieChimni https://t.co/Z8Fy2fj7oS

[Andrew P @pushandr_]

@RNAiAnalyst indeed disappointing update, they not even mention any other tech they have apart nucleases, previous corporate presentation included detailed description of base, prime and cast editors. I guess they dont have legal resources to infringe or challenge prime patents as crispr do

[Andrew P @pushandr_]

@zhaoweiasu How does it usually look like in terms of licensing agreements? I am a bit concerned about metagenomi

[Andrew P @pushandr_]

@Soeren_Berlin @jawnzilla https://t.co/yo0FwR55Oq

[David R. Liu @davidrliu]

Today in @ScienceMagazine we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells, a collaboration with @SternbergLab.
1/13
https://t.co/ZLHtZm5Gmw

[Andrew P @pushandr_]

@Soeren_Berlin @jawnzilla Hi @Soeren_Berlin don't forget about CAST/evoCAST tech also done by Liu lab and Prime's competitor $MGX. Not sure though if Liu going yo create another company for it in his usual fashion, hope he will just license it to Prime medicine.

[Andrew P @pushandr_]

@RNAiAnalyst Hey @RNAiAnalyst, as $MGX uses a lot of $PRME and Broad institute IP, do you see any patent infringement risks here? How such disputes usually resolved in RNAi space as an example?

[Andrew P @pushandr_]

@Biotech2k1 Hey @Biotech2k1 what do you think about a potential patent dispute between $mgx and $prime? I think institutes affiliated with prime hold not only ip for prime editing but also CAST IP, so I have a real concern for Metagenomi infringement here. How it usually resolved in biotech?

[Andrew P @pushandr_]

@CrisprCIO not even close to commercialization but there are some rna based approaches

https://t.co/TD5kZB4gkw